Cardiff Oncology (NASDAQ:CRDF) interim CEO Mani Mohindru outlined updated clinical results and development plans for the ...
Phase 1b study to assess the safety of neoadjuvant trifluridine/tipiracil with concurrent radiation in resectable stage II/III rectal cancer. This is an ASCO Meeting Abstract from the 2023 ASCO ...
– 100% response rate in 1L left-sided mCRC (n=8, confirmed and unconfirmed) – 62% response rate in 2L left- and right-sided mCRC (n=13, confirmed and unconfirmed) “Petosemtamab’s unique mechanism of ...
- Petosemtamab in combination with FOLFOX /FOLFIRI (1L and 2L mCRC) and as monotherapy (3L+ mCRC), demonstrates antitumor activity and a manageable safety profile UTRECHT, The Netherlands and ...
A fixed-sequence, open-label study to determine the activity of SCH 717454 (robatumumab) as assessed by positron emission tomography in patients with relapsed or recurrent colorectal cancer. Phase I ...
PLYMOUTH MEETING, PA [September 5, 2024] — New research just-published online by JNCCN—Journal of the National Comprehensive Cancer Network finds that for many commonly used treatment regimens ...
Merck, a leading science and technology company, will present data at the ESMO 18 th World Congress on Gastrointestinal Cancer (WCGC) from the pivotal Phase III TAILOR study in patients from China, ...
Yakult Honsha has patented a method for predicting the effectiveness of FOLFOX or FOLFIRI regimens in treating stage IV colorectal cancer. By measuring copy number gains in specific chromosome regions ...
Prognostic factors for AKI include old age, low body mass index (BMI), proteinuria at baseline, as well as regimens containing bevacizumab, most notably, FOLFIRI + bevacizumab. The findings can help ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results